Pharmaceutical

GC Pharma Lights Up to Celebrate ‘World Hemophilia Day’

Biotechnology, Health, Genetics, Pharmaceutical, Cardiology
Sunday, April 18, 2021 - 3:09am

Hemophilia A is more common than hemophilia B; hemophilia A affects about 150,000 people, whereas hemophilia B affects about 30,000 people worldwide.

Key Points: 
  • Hemophilia A is more common than hemophilia B; hemophilia A affects about 150,000 people, whereas hemophilia B affects about 30,000 people worldwide.
  • Treatment regimens typically include on-demand and/or regular prophylactic infusions of factor replacement therapy to control or prevent the risk of bleeding.
  • Headquartered in South Korea, GC Pharma is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions for more than half a century.
  • Green Cross Corporation updated its corporate brand to GC Pharma in early 2018.

Autobahn Therapeutics Presents Preclinical, Proof of Concept Data for ABX-002 for the Treatment of Adrenomyeloneuropathy

Biotechnology, Other Health, Health, Pharmaceutical, Clinical trials
Saturday, April 17, 2021 - 1:00pm

The data will be highlighted in a poster presentation at the American Academy of Neurology Annual Meeting, which is being held virtually from April 17-22, 2021.

Key Points: 
  • The data will be highlighted in a poster presentation at the American Academy of Neurology Annual Meeting, which is being held virtually from April 17-22, 2021.
  • \xe2\x80\x9cAMN is a highly debilitating disease, leading to motor disabilities, fatigue, ataxia, sensory loss, adrenal insufficiency, incontinence and impotence, with no currently approved treatments.
  • Autobahn is leveraging its brain-targeting chemistry platform to unlock new therapeutic opportunities through precision tuning of the central exposure of its molecules.
  • The company\xe2\x80\x99s pipeline is led by ABX-002, a thyroid hormone receptor beta agonist for the treatment of adrenomyeloneuropathy (AMN), a rare genetic disorder.

Global COVID-19 Vaccine Inequalities Are Scandalous, Says AHF

Infectious diseases, LGBTQ+, Public policy, Government, Other Health, Biotechnology, Pharmaceutical, Consumer, Health, Public policy, Other Policy Issues
Saturday, April 17, 2021 - 12:35am

\xe2\x80\x9cThe innovation and ambition it took to produce dozens of different COVID-19 vaccines in record time show we can accomplish monumental scientific achievements.

Key Points: 
  • \xe2\x80\x9cThe innovation and ambition it took to produce dozens of different COVID-19 vaccines in record time show we can accomplish monumental scientific achievements.
  • But the greed and inequality we\xe2\x80\x99ve seen since prove that there must also be a global collective will to ensure we can vaccinate our world.
  • Instead of learning and improving, the global response is unraveling.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210416005582/en/\n'

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biotechnology, Pharmaceutical, Health
Friday, April 16, 2021 - 11:35pm

b'Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on April 15, 2021, the Compensation Committee of its Board of Directors granted to 17 new employees inducement stock options to purchase an aggregate of 50,785 shares of its common stock and 20,490 inducement restricted stock units ("RSUs").

Key Points: 
  • b'Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on April 15, 2021, the Compensation Committee of its Board of Directors granted to 17 new employees inducement stock options to purchase an aggregate of 50,785 shares of its common stock and 20,490 inducement restricted stock units ("RSUs").
  • For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995.
  • Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena\'s filings with the Securities and Exchange Commission.
  • Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210416005579/en/\n'

Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oncology, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology
Friday, April 16, 2021 - 9:30pm

Each of the options was granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).\nVicineum, a locally administered fusion protein, is Sesen Bio\xe2\x80\x99s lead product candidate being developed for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

Key Points: 
  • Each of the options was granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).\nVicineum, a locally administered fusion protein, is Sesen Bio\xe2\x80\x99s lead product candidate being developed for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
  • In prior clinical trials conducted by Sesen Bio, EpCAM has been shown to be overexpressed in NMIBC cells with minimal to no EpCAM expression observed on normal bladder cells.
  • Sesen Bio is currently in the follow-up stage of a Phase 3 registration trial in the US for the treatment of BCG-unresponsive NMIBC.
  • Additionally, Sesen Bio believes that cancer cell-killing properties of Vicineum promote an anti-tumor immune response that may potentially combine well with immuno-oncology drugs, such as checkpoint inhibitors.

Publix COVID-19 Vaccination Online Reservation System to Remain Open

Infectious diseases, Health, Retail, Pharmaceutical, Supermarket
Friday, April 16, 2021 - 7:08pm

b'In all seven states in which Publix operates, the company\xe2\x80\x99s online reservation system will remain continuously open to book available appointments to receive the Moderna COVID-19 vaccination, as long as we continue to receive vaccine doses and barring unforeseen circumstances.

Key Points: 
  • b'In all seven states in which Publix operates, the company\xe2\x80\x99s online reservation system will remain continuously open to book available appointments to receive the Moderna COVID-19 vaccination, as long as we continue to receive vaccine doses and barring unforeseen circumstances.
  • However, appointments may not be available at all locations at all times.\nThe system is currently open for appointments in Georgia, Florida, South Carolina and Virginia.
  • Individuals can use the online reservation system to learn if appointments are available at their nearby store.
  • Appointments cannot be made by calling Publix or the Publix Pharmacy.\nVaccinations are provided to eligible individuals, by appointment only, while supplies last, and at no cost to the individual.

OKR Financial Raises $150 Million to Support Early-Stage Innovators With Immediate Capital

Research, Finance, Consulting, Clinical trials, Professional services, Biotechnology, Pharmaceutical, Health, Science, Other Science
Friday, April 16, 2021 - 6:53pm

b'OKR Financial, one of Canada\xe2\x80\x99s leading providers of non-dilutive financing, is announcing its raise of $150 million to support growing businesses looking to access SR&ED tax credits, asset-based loans, government grants, or equity deals.

Key Points: 
  • b'OKR Financial, one of Canada\xe2\x80\x99s leading providers of non-dilutive financing, is announcing its raise of $150 million to support growing businesses looking to access SR&ED tax credits, asset-based loans, government grants, or equity deals.
  • Solving the problem of waiting for government agencies to process tax claims or grant applications, OKR Financial\xe2\x80\x99s help allows companies to access funding fast, extending the runway so these companies can continue to grow while they await their government funds.\nThe OKR team has strategically chosen to partner with Ayming Canada, a global consulting firm which helps businesses maximize government funding and tax credits.
  • This is where Ayming\xe2\x80\x99s expertise comes in,\xe2\x80\x9d says Harry Singh, President & Managing Partner of Ayming Canada.\nThe Scientific Research & Experimental Development (SR&ED) Tax Credit program provides over $3 billion to over 20,000 businesses annually, and there are over 2000 various government grants available, with more being announced all the time.
  • OKR operates a family of private funds that provide non-dilutive financing solutions to SMEs by leveraging Federal & Provincial SR&ED tax credits and Government funded programs, providing the pathway to equity financing when companies are ready to scale up.\n'

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma....

Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical trials
Friday, April 16, 2021 - 6:10pm

In patients receiving OPDIVO monotherapy, immune-mediated colitis occurred in 2.9% (58/1994) of patients, including Grade 3 (1.7%) and Grade 2 (1%).\nOPDIVO can cause immune-mediated hepatitis.

Key Points: 
  • In patients receiving OPDIVO monotherapy, immune-mediated colitis occurred in 2.9% (58/1994) of patients, including Grade 3 (1.7%) and Grade 2 (1%).\nOPDIVO can cause immune-mediated hepatitis.
  • Withhold OPDIVO depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information).
  • In patients receiving OPDIVO monotherapy as a 60-minute infusion, infusion-related reactions occurred in 6.4% (127/1994) of patients.
  • Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: first results of the CheckMate 649 study.

2020 Report on Insulin Resistance R&D Pipeline Analysis - Small Insulin Resistance Companies Look for Licensing and Collaboration Partners - ResearchAndMarkets.com

Science, Other Science, Research, Pharmaceutical, Managed care, Health, Diabetes, Other Health
Friday, April 16, 2021 - 6:00pm

b'The "Insulin Resistance R&D Pipeline Analysis Report, Q4 2020" report has been added to ResearchAndMarkets.com\'s offering.\nThe Q4 Insulin Resistance pipeline report is part of the VPA Metabolic Disorder disease pipeline service.

Key Points: 
  • b'The "Insulin Resistance R&D Pipeline Analysis Report, Q4 2020" report has been added to ResearchAndMarkets.com\'s offering.\nThe Q4 Insulin Resistance pipeline report is part of the VPA Metabolic Disorder disease pipeline service.
  • This quarterly review describes the pipeline of drugs under development for Insulin Resistance, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.\nThe comprehensive report on the indication presents Insulin Resistance disease overview, Insulin Resistance types, Insulin Resistance symptoms, causes, and FDA/EMA approved treatment options.\nThe year 2020 witnessed progress in innovations and the number of pipeline agents researched for Insulin Resistance indication.
  • The report presents near-term and long-term pipeline development trends and potential insights.\nThe report analyzes the development progress, current status, investments, partnerships, and other developments of 8 companies.
  • Further, the presence of large companies and stringent regulations act as barriers for Insulin Resistance pipeline development companies.

Global RNAi Technologies, Markets & Companies Report 2021 Featuring 167 Companies & 229 Collaborations - ResearchAndMarkets.com

Biotechnology, Pharmaceutical, Health, Other Health
Friday, April 16, 2021 - 5:57pm

b'The "RNAi - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com\'s offering.\nThe markets for RNAi are difficult to define as no RNAi-based product is approved yet but several are in clinical trials.

Key Points: 
  • b'The "RNAi - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com\'s offering.\nThe markets for RNAi are difficult to define as no RNAi-based product is approved yet but several are in clinical trials.
  • The major use of RNAi reagents is in research but it partially overlaps that of drug discovery and therapeutic development.
  • Markets are also analyzed according to technologies and the use of siRNAs, miRNAs, etc.\nProfiles of 167 companies involved in developing RNAi technologies are presented along with 229 collaborations.
  • They are a mix of companies that supply reagents and technologies (nearly half of all) and companies that use the technologies for drug discovery.